Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices

References

• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.
   PubMedGoogle Scholar
• World Health Organization. Fact sheet. Meningococcal meningitis. Available from: https://www.who.int/en/news-room/fact-sheets/detail/meningococcal-meningitis. Accessed: May 2020.
   Google Scholar
• Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397–403.
   PubMed Web of Science ®Google Scholar
• Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–783.
   PubMed Web of Science ®Google Scholar
• Wang B, Santoreneos R, Giles L, et al., Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21): 2768–2782.
   PubMed Web of Science ®Google Scholar
• Dastouri F, Hosseini AM, Haworth E, et al., Complications of serogroup B meningococcal disease in survivors: a review. Infect Disord Drug Targets. 2014;14(3): 205–212.
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. Available from: https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=36. Accessed: Apr 2021.
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2017. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2017.pdf. Accessed: Nov 2020.
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2018. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2018.pdf. Accessed: May 2020.
   Google Scholar
• Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020;8(10):1521.
   Web of Science ®Google Scholar
• European Medicines Agency. Bexsero. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/bexsero. Accessed: Jun 2021.
   Google Scholar
• Harrison LH, Pelton SI, Wilder-Smith A, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29(18):3363–3371.
   PubMedGoogle Scholar
• Martinón-Torres F, Banzhoff A, Azzari C, et al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J Infect. 2021;83(1):17–26.
   PubMed Web of Science ®Google Scholar
• Rodrigues FMP, Marlow R, Simões MJ, et al. Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal. Jama. 2020;324(21):2187–2194.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317.
   PubMed Web of Science ®Google Scholar
• Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018;2(6):395–403.
   PubMedGoogle Scholar
• Ladhani SN, Campbell H, Andrews N, et al. First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England. Clin Infect Dis. 2021;73(7):e1661–e1668.
   PubMed Web of Science ®Google Scholar
• Biolchi A, De Angelis G, Moschioni M, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38(47):7542–7550.
   PubMed Web of Science ®Google Scholar
• Abara WE, Jerse AE, Hariri S, et al. Planning for a gonococcal vaccine: a narrative review of vaccine development and public health implications. Sex Transm Dis. 2021;48(7):453–457.
   PubMed Web of Science ®Google Scholar
• Longtin J, Dion R, Simard M, et al. Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of Quebec, Canada. Open Forum Infect Dis. 2017;4:S734–S735.
   Google Scholar
• Patton ME, Stephens D, Moore K, et al. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509–513.
   PubMed Web of Science ®Google Scholar
• Soeters HM, McNamara LA, Blain AE, et al. University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013-2018. Emerg Infect Dis. 2019;25(3):434–440.
   PubMed Web of Science ®Google Scholar
• O’Ryan M, Stoddard J, Toneatto D, et al., A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74(1): 15–30.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, Masignani V, et al. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17(12):1111–1121.
   PubMed Web of Science ®Google Scholar
• Borrow R, Taha MK, Giuliani MM, et al., Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence. J Infect. 2020;81(6): 862–872.
   PubMed Web of Science ®Google Scholar
• Govern d’Andorra. Ministeri de Salut. Nota informativa. Recomanacions sobre l’administració de la vacunacióenfront del meningococ B (Bexsero). February 2016. Available from: https://www.salut.ad/images/stories/Salut/pdfs/temes_salut/Recomanacions_Vacuna_Bexero.pdf. Accessed: May 2020.
   Google Scholar
• Ministry of Health Argentina. Argentina’s meningococcal vaccination strategy guidelines. Available from: https://bancos.salud.gob.ar/recurso/huespedes-especiales-estrategia-de-vacunacion-contra-meningococo-de-argentina Accessed 2021 Dec 8.
   Google Scholar
• Australian Government Department of Health. National Immunisation Program. Meningococcal vaccination schedule from 2020 Jul 1. Available from: https://www.health.gov.au/sites/default/files/documents/2020/06/national-immunisation-program-meningococcal-vaccination-schedule-from-1-july-2020-clinical-advice-for-vaccination-providers.pdf. Accessed: Oct 2020.
   Google Scholar
• Government of South Australia. Meningococcal B immunisation program. Available from: https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/conditions/immunisation/immunisation+programs/meningococcal+b+immunisation+program Accessed: 2021 Dec 8.
   Google Scholar
• Federal Ministry of Health Austria. Impfplan Osterreich. Available from: https://www.sozialministerium.at/Themen/Gesundheit/Impfen/Impfplan-%C3%96sterreich.html Accessed 2021 Dec 8.
   Google Scholar
• Superior Council of Health Belgium. CSS-9485, revision 2019. Available from: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/shc_9485_meningococcal_vaccination_2019_1.pdf Accessed: 2021 Dec 8.
   Google Scholar
• Brazilian Society of Pediatrics. Calendário de Vacinação da SBP 2020. Available from: https://www.sbp.com.br/fileadmin/user_upload/22268g-DocCient-Calendario_Vacinacao_2020.pdf. Accessed 2021 Dec 8.
   Google Scholar
• Public Health Canada. Meningococcal vaccine. Canadian immunization guide. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html Accessed 2021 Dec 8.
   Google Scholar
• Public Health Agency of Canada. NACI statement 2014. Available from: http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-104-2014-eng.pdf. Accessed 2021 Dec 8.
   Google Scholar
• Ministry of Health Chile. Recomendaciones para la vacunación de pacientes con necesidades especiales por patologías o situaciones de riesgo. Available from: https://vacunas.minsal.cl/wp-content/uploads/2020/02/Recomendaciones-para-la-vacunación-de-pacientes-con-necesidades-especiales.pdf. Accessed 2021 Dec 8.
   Google Scholar
• Ministry of Health Croatia. National Immunization programme. Available from: https://zdravlje.gov.hr/UserDocsImages/2020%20Programi%20i%20projekti/Izmjene%20i%20dopuna%20Provedbenog%20programa%20cijepljenja%20II%20u%202020.pdf Accessed 2021 Dec 8.
   Google Scholar
• Cyprus Paediatrics Society. Recommendations. Available from: http://www.child.org.cy/vaccination-2017/. Accessed 2021 Dec 8.
   Google Scholar
• Czech National Institute of Public Health. Očkování proti meningokokovým onemocněním. Available from: http://www.szu.cz/ockovani-proti-meningokokovym-onemocnenim. Accessed 2021 Dec 8.
   Google Scholar
• Czech Vaccinology Society. News: payment for vaccination of children against meningococci from 1.5.2020. Available from: https://www.vakcinace.eu/novinky. Accessed 2021 Dec 8.
   Google Scholar
• Czech Vaccinology Society. Recommendations of the Czech Vaccinology Society of the J. E. Purkyně Czech Medical Association for Vaccination against Invasive Meningococcal Disease Available from: http://www.szu.cz/uploads/IMO/2020_Recommendation_vaccination_IMD.pdf Accessed 2021 Dec 8.
   Google Scholar
• Finnish Institute for Health and Welfare. Meningococcus B vaccine. Available from: https://thl.fi/en/web/infectious-diseases-and-vaccinations/vaccines-a-to-z/meningococcal-vaccines/meningococcus-b-vaccine. Accessed 2021 Dec 8.
   Google Scholar
• Haut Conseil de la Santé Publique. HCSPA Bexsero recommendations. Available from: http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20131025_vaccmeningocoqueBBexsero.pdf. Accessed 2021 Dec 8.
   Google Scholar
• Greek Paediatric Society. EIA recommendations for vaccines. Available from: http://e-child.gr/update-education/education-recommendations-for-vaccinations/. Accessed 2021 Dec 8.
   Google Scholar
• Robert Koch Institute. Recommendations of the standing committee on vaccination (STIKO) at the Robert Koch Institute – 2017/2018. Available from: https://www.rki.de/EN/Content/infections/Vaccination/recommandations/34_2017_engl.pdf?__blob=publicationFile Accessed 2021 Dec 8.
   Google Scholar
• National Immunisation Office Republic of Ireland. Current schedule. Available from: https://www.hse.ie/eng/health/immunisation/pubinfo/currentschedule.html. Accessed 2021 Dec 8.
   Google Scholar
• Israel. IDAC 2019. Available from: https://www.health.gov.il/Services/Committee/IDAC/Documents/CSV_02012019.pdf. Accessed 2021 Dec 8.
   Google Scholar
• Ministero della Salute Italy. Piano Nazionale prevenzione vaccinale 2017-2019. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf. Accessed: May 2020.
   Google Scholar
• Ministry of Health Republic of Lithuania. Dėl lietuvos respublikos sveikatos apsaugos ministro. 2015 m. BIRŽELIO 12 d. įsakymo nr. V-757 „DĖL Lietuvos respublikos vaikų profilaktinių skiepijimų kalendoriaus patvirtinimo“ pakeitimo. Available from: https://e-seimas.lrs.lt/portal/legalAct/lt/TAD/f4a925d0f50f11e79a1bc86190c2f01a?positionInSearchResults=0&searchModelUUID=1561434a-b283-4be2-87f5-4f556ad37c32. Accessed: May 2020.
   Google Scholar
• Higher Council of Infectious Diseases Luxembourg. La vaccination contre le meningocoque groupe B. Available from: http://sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/meningite/2018-avis-vaccination-meningocoque-groupe-b.pdf. Accessed 2021 Dec 8.
   Google Scholar
• Ministry for Health Malta. National immunisation schedule 2020. Available from: https://deputyprimeminister.gov.mt/en/phc/pchyhi/Pages/National-Immunisation-Schedule.aspx. Accessed: Apr 2021.
   Google Scholar
• The Immunisation Advisory Centre New Zealand. Bexsero. Available from:http://www.immune.org.nz/vaccines/available-vaccines/bexsero Accessed: Nov 2020.
   Google Scholar
• Norwegian Institute of Public Health. Meningococcal disease vaccine. Available from: https://www.fhi.no/en/op/vaccination-guidance/vaccines-offered-in-norway/meningococcal-disease/. Accessed 2021 Dec 8.
   Google Scholar
• Ministry of Health Poland. Programu Szczepień Ochronnych na rok 2019. Available from: https://gis.gov.pl/wp-content/uploads/2018/01/akt.pdf. Accessed 2021 Dec 8.
   Google Scholar
• Sociedade de Infeciologia Pediatrica e Sociedade Portuguesa de Pediatrica. Recomendações sobre vacinas extra programa nacional de vacinação. Available from: https://www.spp.pt/UserFiles/file/Seccao_Infecciologia/recomendacoes%20vacinas_sip_final_28set_2.pdf. Accessed 2021 Dec 8.
   Google Scholar
• Gabinete do Secretário de Estado da Saúde. Despacho n.° 12434/2019. Available from: https://dre.pt/dre/LinkFicheiroAntigo?conteudoId=127608823. Accessed 2021 Dec 8.
   Google Scholar
• Istituto per la Sicurezza Sociale San Marino. Vaccinazioni raccomandate. Available from: http://www.iss.sm/on-line/home/vaccini-e-vaccinazioni/vaccinazioni-raccomandate.html. Accessed 2021 Dec 8.
   Google Scholar
• National Institute za Javno Zdravje Slovenia. Available from: https://www.nijz.si/sl/publikacije/cepljenje-otrok-knjizica-za-starse. Accessed 2021 Dec 8.
   Google Scholar
• Moreno-Pérez D, Álvarez García FJ, Álvarez Aldeán J, et al. Immunisation schedule of the Spanish association of paediatrics: 2019 recommendations. An Pediatr (Engl Ed). 2019;90(1):56.e51–56.e59.
   Web of Science ®Google Scholar
• Swedish Public Health Agency. Recommendations on preventive measures against invasive meningococcal infection. Available from: https://www.folkhalsomyndigheten.se/contentassets/941f1dd281b24e75b6e6d46d490b4d1d/rekommendationer-om-forebyggande-atgarder-mot-invasiv-meningokockinfektion.pdf. Accessed 2021 Dec 8.
   Google Scholar
• Public Health England. Immunisation against infectious disease. Meningococcal: the green book, chapter 22. Available from: https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22. Accessed: Dec 2021.
   Google Scholar
• Uruguayan Society of Pediatrics. Inform tecnico - enfermedad meningococcia en Uruguay 2017. Available from: https://www.sup.org.uy/2017/12/21/informe-tecnico-enfermedad-meningococcia-en-uruguay-2017/. Accessed 2021 Dec 8.
   Google Scholar
• Mbaeyi S, Bozio C, Duffy J. Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. MMWR Recomm Rep. 2020;69:1–41.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–2782.
   PubMed Web of Science ®Google Scholar
• National Immunisation Office Republic of Ireland. Primary childhood immunisation schedule. Available from: https://www.hse.ie/eng/health/immunisation/pubinfo/pcischedule/immschedule/. Accessed: May 2020.
   Google Scholar
• Istituto per la Sicurezza Sociale San Marino. Delibera n.38 del 21/03/18 Modifica calendario vaccinale per le vaccinazioni obbligatorie e raccomandate. Available from: http://www.iss.sm/on-line/home/vaccini-e-vaccinazioni/vaccinazioni-obbligatorie-a-san-marino/riferimenti-legislativi.html. Accessed: Apr 2021.
   Google Scholar
• Ceska Vakcinologicka Spolecnost CLS JEP. Available from: https://www.vakcinace.eu/. Accessed: Jul 2020.
   Google Scholar
• Gabinete do Secretário de Estado da Saúde. Aprova o novo esquema vacinal do Programa Nacional de Vacinação (PNV), revo-gando, com exceção do seu n. 6, o Despacho n.° 10441/2016, de 9 de agosto. Available from: https://dre.pt/application/conteudo/127608823. Accessed: Aug 2020.
   Google Scholar
• Haute Autorité de Santé (HAS). Stratégie de vaccination pour la prévention des infections invasives à méningocoques: le sérogroupe B et la place de BEXSERO®. Available from: https://www.has-sante.fr/jcms/p_3066921/fr/strategie-de-vaccination-pour-la-prevention-des-infections-invasives-a-meningocoques-le-serogroupe-b-et-la-place-de-bexsero. Accessed 2021 Nov 27.
   Google Scholar
• European Centre for Disease Prevention and Control. ECDC Vaccine Scheduler. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=−1. Accessed: Aug 2020.
   Google Scholar
• Marshall HS, Lally N, Flood L, et al. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Med J Aust. 2020;212(2):89–93.
   PubMed Web of Science ®Google Scholar
• Public Health England. The routine immunisation schedule. From June 2020. Available from: https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule. Accessed: Apr 2021.
   Google Scholar
• Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27 Suppl 2:B20–29.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. JCVI interim position statement on use of Bexsero meningococcal B vaccine in the UK. July 2013. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/224896/JCVI_interim_statement_on_meningococcal_B_vaccination_for_web.pdf. Accessed: May 2020.
   Google Scholar
• Moxon R, Snape MD. The price of prevention: what now for immunisation against meningococcus B? Lancet. 2013;382(9890):369–370.
   PubMed Web of Science ®Google Scholar
• Blewitt J. Immunisation against meningococcus B. Lancet. 2013;382(9895):857–858.
   PubMedGoogle Scholar
• Head C. Immunisation against meningococcus B. Lancet. 2013;382(9896):935.
   PubMedGoogle Scholar
• Joint Committee on Vaccination and Immunisation. JCVI position statement on use of Bexsero meningococcal B vaccine in the UK. March 2014. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/294245/JCVI_Statement_on_MenB.pdf. Accessed: May 2020.
   Google Scholar
• Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. Bmj. 2014;349:g5725.
   PubMed Web of Science ®Google Scholar
• Isitt C, Cosgrove CA, Ramsay ME, et al. Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. Arch Dis Child. 2020;105(8):784–790.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Giuliani MM, Biolchi A, et al. Effectiveness of meningococcal B vaccine against endemic hypervirulent Neisseria meningitidis W strain, England. Emerg Infect Dis. 2016;22(2):309–311.
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123–2131.
   PubMed Web of Science ®Google Scholar
• Harcourt S, Morbey RA, Bates C, et al. Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data. Vaccine. 2018;36(4):565–571.
   PubMed Web of Science ®Google Scholar
• National Immunisation Office Republic of Ireland. Immunisation. Meningococcal B. Available from: https://www.hse.ie/eng/health/immunisation/hcpinfo/othervaccines/meningococcalb/#Paracetamol%20after%20MenB%20vaccine. Accessed: Apr 2021.
   Google Scholar
• Bennett D, O’Lorcain P, Morgan S, et al. Epidemiology of two decades of invasive meningococcal disease in the Republic of Ireland: an analysis of national surveillance data on laboratory-confirmed cases from 1996 to 2016. Epidemiol Infect. 2019;147:e142.
   PubMed Web of Science ®Google Scholar
• Kabir Z, Manning PJ, Holohan J, et al. Active smoking and second-hand-smoke exposure at home among Irish children, 1995-2007. Arch Dis Child. 2010;95(1):42–45.
   PubMed Web of Science ®Google Scholar
• National Centre for Pharmacoeconomics. Economic evaluation of a universal meningitis B vaccination programme in Ireland. Available from: http://www.ncpe.ie/wp-content/uploads/2018/02/Meningitis-B-vaccine-Feb-2014.pdf. Accessed: Nov 2020.
   Google Scholar
• Rota M, Bella A, D’Angelo F, et al. Vaccinazione anti-meningococco B: dati ed evidenze disponibili per l’introduzione in nuovi nati e adolescenti. Roma: istituto Superiore di Sanità; 2015. (Rapporti ISTISAN 15/12). Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwi3juDajNX0AhVDZMAKHTBLA34QFnoECAIQAQ&url=https%3A%2F%2Fwww.scienzainrete.it%2Ffiles%2F15_12.pdf&usg=AOvVaw1E2zXD1bsfZKm46V6TRztG. Accessed: Aug 2020.
   Google Scholar
• Azzari C, Canessa C, Lippi F, et al. Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing. Vaccine. 2014;32(10):1187–1191.
   PubMed Web of Science ®Google Scholar
• Gasparini R, Amicizia D, Lai PL, et al. Meningococcal B vaccination strategies and their practical application in Italy. J Prev Med Hyg. 2015;56(3):E133–139.
   PubMedGoogle Scholar
• Stefanelli P, Miglietta A, Pezzotti P, et al. Increased incidence of invasive meningococcal disease of serogroup C / clonal complex 11, Tuscany, Italy, 2015 to 2016. Euro Surveill. 2016;21(12). https://doi.org/10.2807/1560-7917.ES.2016.21.12.30176.
   Google Scholar
• Covolo L, Croce E, Moneda M, et al. Meningococcal disease in Italy: public concern, media coverage and policy change. BMC Public Health. 2019;19(1):1061.
   PubMed Web of Science ®Google Scholar
• Azzari C, Nieddu F, Moriondo M, et al. Underestimation of invasive meningococcal disease in Italy. Emerg Infect Dis. 2016;22(3):469–475.
   PubMed Web of Science ®Google Scholar
• Alfonsi V, D’Ancona F, Giambi C, et al. Current immunization policies for pneumococcal, meningococcal C, varicella and rotavirus vaccinations in Italy. Health Policy. 2011;103(2–3):176–183.
   PubMed Web of Science ®Google Scholar
• Gasparini R, Landa P, Amicizia D, et al. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: a cost-effectiveness analysis. Hum Vaccin Immunother. 2016;12(8):2148–2161.
   PubMed Web of Science ®Google Scholar
• Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two Italian regions using different vaccination schedules: a five-year retrospective observational study (2014-2018). Vaccines (Basel). 2020;8(3):469.
   Web of Science ®Google Scholar
• Nicolosi L, Rizzo C, Gattinara GC, et al. Safety and tolerability of meningococcus B vaccine in patients with chronical medical conditions (CMC). Ital J Pediatr. 2019;45(1):133.
   PubMed Web of Science ®Google Scholar
• Pace D, Gauci C, Barbara C. The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta. Eur J Clin Microbiol Infect Dis. 2020;39(10):1885–1897.
   PubMed Web of Science ®Google Scholar
• Krizova P, and Honskus M. Genomic surveillance of invasive meningococcal disease in the Czech Republic, 2015-2017. PLoS One. 2019;14(7):e0219477.
   PubMed Web of Science ®Google Scholar
• Repositório Científico do Instituto Nacional de Saúde. Epidemiology of invasive meningococcal disease in Portugal in the last decade – 2007-2016. Available from: http://repositorio.insa.pt/handle/10400.18/5176. Accessed: Aug 2020.
   Google Scholar
• Capitano B, Dillon K, LeDuc A, et al. Experience implementing a university-based mass immunization program in response to a meningococcal B outbreak. Hum Vaccin Immunother. 2019;15(3):717–724.
   PubMed Web of Science ®Google Scholar
• La EM, Garbinsky D, Hunter S, et al. Meningococcal B vaccination coverage among older adolescents in the United States. Vaccine. 2021;39(19):2660–2667.
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–327.
   PubMed Web of Science ®Google Scholar
• McMillan M, Wang B, Koehler AP, et al. Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents. Clin Infect Dis. 2021;73(1):e233–237.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Koehler AP, Wang B, et al. Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia. Vaccine. 2020;38(37):5914–5922.
   PubMed Web of Science ®Google Scholar
• Haute Autorité de Santé (HAS). La HAS recommande la vaccination des nourrissons contre le méningocoque B. Les pros de la petit enfance. Available from: https://lesprosdelapetiteenfance.fr/la-has-recommande-la-vaccination-des-nourrissons-contre-le-meningocoque-b. Accessed 2021 Nov 27.
   Google Scholar
• World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme. 2014. Available from: https://apps.who.int/iris/bitstream/handle/10665/111548/9789241506892_eng.pdf;jsessionid=75F9B7C9D6282EC802B908056D1EEE98?sequence=1. Accessed: Jul 2020.
   Google Scholar
• Christensen H, Al-Janabi H, Levy P, et al. Economic evaluation of meningococcal vaccines: considerations for the future. Eur J Health Econ. 2020;21(2):297–309.
   PubMed Web of Science ®Google Scholar
• Stawasz A, Huang L, Kirby P, et al. Health technology assessment for vaccines against rare, severe infections: properly accounting for serogroup B meningococcal vaccination’s full social and economic benefits. Front Public Health. 2020;8:261.
   PubMed Web of Science ®Google Scholar
• Beck E, Klint J, Neine M, et al. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91–104.
   PubMed Web of Science ®Google Scholar
• Sevilla J, Tortorice D, Kantor D, et al. PIN43 Lifecycle-model-based economic evaluation of infant meningitis B vaccination in the UK. Value Health. 2019;22(Supplement 3):S647.
   Google Scholar
• Mauskopf J, Masaquel C, Huang L. Evaluating vaccination programs that prevent diseases with catastrophic health outcomes: how can we capture the value of risk reduction? Value Health. 2021;24(1):86–90.
   PubMed Web of Science ®Google Scholar